Veraxa Biotech AG - Post de-SPAC
VRXAReported to SECin USCIK 0002079109Filings at SEC EDGAR
VRXA is one of 2 listed share classes under this CIK; the filings below cover all of them.
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 2 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
Filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Baumann Oliver Rolf— | Open-market buy | $75,00050,000 shares | Aug 31, 2026 | Baumann Oliver Rolf | $75,000 | Open-market buy | 50,000 | Aug 31, 2026 |
| Antz Christoph RudigerChief Executive Officer | Open-market buy | $7,6505,000 shares | Aug 31, 2026 | Antz Christoph RudigerChief Executive Officer | $7,650 | Open-market buy | 5,000 | Aug 31, 2026 |